Augmentin, a combination of amoxicillin and clavulanate, demonstrates activity against a limited range of anaerobic bacteria. Its effectiveness primarily stems from amoxicillin’s action against susceptible strains. Remember that clavulanate’s role is to inhibit beta-lactamases, enzymes produced by some bacteria that inactivate amoxicillin. This means that Augmentin may be more effective than amoxicillin alone against certain anaerobic bacteria producing these enzymes.
Specific Anaerobes
Augmentin shows activity against some Bacteroides fragilis group members, but resistance is increasingly common. It also covers some strains of Peptostreptococcus species and Clostridium perfringens, although susceptibility varies significantly. Always consult local antibiograms for current resistance patterns before prescribing. Keep in mind that many anaerobic infections involve a mix of bacteria, requiring a broader-spectrum antibiotic regimen. For more severe or mixed anaerobic infections, consider alternatives like metronidazole or carbapenems.
Limitations
Augmentin lacks significant activity against many clinically relevant anaerobic species, including Clostridium difficile. This limitation mandates careful consideration when treating suspected anaerobic infections. Clinical response is the ultimate guide to determining Augmentin’s efficacy in a particular case, and culture and sensitivity testing should always guide antibiotic selection. The spectrum of anaerobic bacteria susceptible to Augmentin is narrow, and should not be the sole basis for empirical therapy in polymicrobial infections.
